# NCT02519452 (NCT02519452)

> A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma

No report yet. It can be ordered.

- Drugs tested: subcutaneous daratumumab
- Indication: relapsed or refractory multiple myeloma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02519452
- Phase: PHASE1
- Status: COMPLETED
- Sponsor: Janssen Research & Development, LLC
- Conditions: Multiple Myeloma
- Interventions: Daratumumab Subcutaneous (SC) Administration; Recombinant Human Hyaluronidase [rHuPH20]) SC Administration
- Enrollment: 120
- Primary outcome: Serum Trough Concentrations (Ctrough) of Daratumumab
- Primary outcome: Part 1, 2 and 3: Number of Participants with Adverse Events (AEs) and Serious AEs

## Indexed commentary on NCT02519452 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct02519452